Market news

Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%. Recent trading has been choppy, with a 1-day share price return of 2.11% following a 7-day share price return that fell 9.22% and a 30-day share price return down 17.58%. Despite this, Inhibrx Biosciences still shows a year-to-date share price return of 35.54% and a very large 1-year total shareholder return of 214.79%. This...

Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]

Jon Faiz Kayyem, Director, on September 16, 2026, executed a purchase for 5,000 shares in Inhibrx Bi

Lappe's purchase through family trusts boosts his beneficial ownership to 950,000 shares, or 6% of outstanding equity, as Inhibrx trades near $114 following a 293% gain over the past year.

Detailed price information for Circle Internet Group Cl A (CRCL-N) from The Globe and Mail including charting and trades.

Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 a

Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate princi

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.